Tarceva 150 mg (Erlotinib 150 mg) by Roche.
Indications: EGFR mutation-positive locally advanced or metastatic NSCLC; metastatic pancreatic cancer with gemcitabine.
Administration: Oral, once daily at least 1 hour before or 2 hours after food (150 mg NSCLC; 100 mg pancreatic cancer).
Storage: Store below 25–30 °C in the original package. Keep out of the sight and reach of children.
Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only.
| Manufacturer | Roche |
| Active ingredient | Erlotinib 150 mg (as hydrochloride) per tablet — EGFR tyrosine kinase inhibitor. |
| Strength & pack | 30 film-coated tablets. |
| Form | Film-coated tablets |
| Storage | Store below 25–30 °C in the original package. Keep out of the sight and reach of children. |
| Regulatory status | Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only. |